This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1107 (PRO1107) in participants with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B: tumor specific expansion.
Endometrial Cancer, Ovarian Cancer, Triple Negative Breast Cancer, GastroEsophageal Cancer, Non-small Cell Lung Cancer, Urothelial Carcinoma
This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1107 (PRO1107) in participants with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B: tumor specific expansion.
PRO1107 in Patients With Advanced Solid Tumors
-
HonorHealth Research Institute, Scottsdale, Arizona, United States, 85258
Florida Cancer Specialists, Sarasota, Florida, United States, 34236
Massachusetts General Hospital, Boston, Massachusetts, United States, 02114
SCRI Oncology Partners, Nashville, Tennessee, United States, 37203
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, 77030
START Mountain Cancer Center, Salt Lake City, Utah, United States, 78229
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Genmab,
Study Official, STUDY_DIRECTOR, Genmab
2028-06